A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer
Executive Summary
Phase I/II data from Opdivo/Yervoy combination in SCLC provide more evidence that tumor mutation burden is emerging as a biomarker for immunotherapy, but commercial value is unclear and results don't have implications for the all-important CheckMate 227 non-small cell lung cancer trial, analysts say.
You may also be interested in...
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Fresh Wave Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer
Data from AACR puts use of tumor mutation burden as biomarker for lung cancer outcomes in spotlight, but some experts argue the test is not ready for prime time.